Mirati Generates Cautious Optimism With KRAS/PD-1 Combo Data

Adagrasib/Keytruda Show Preliminary ORR Of 71%

 
• By Alaric DeArment
  
earnings report
Mirati reported its third quarter earnings, as well as closely watched combination data for its KRAS G12C inhibitor and Merck's Keytruda • Source: Shutterstock

More from Earnings

More from Business